Oceanpine Capital is a venture capital firm in Hong Kong that focuses on TMT, consumption upgrade, advanced manufacturing, and healthcare sectors. Founded 2017 in Central, Hong Kong Island by David Liguang Chenn, it invests in early stage ventures and late stage ventures. Its portfolio companies include Apexigen, Ansun BioPharma, Enflame, Horizon Robotics, Rgenix, 51zhaoyou.com, Tiger Brokers, and Ansun BioPharma. As of March 2020, Oceanpine Capital has made eight investments. Their most recent investment was on March 24, 2020, when Apexigen raised $65M. Oceanpine Capital has had one exit, which was Tiger Brokers.